

## **Diana E. Pankevich, Ph.D.**

Mobile: (202) 295-7732

E-mail: diana.pankevich@gmail.com

### **PROFILE**

A solutions-oriented policy strategist working at the nexus of science, technology, and healthcare. I work to drive evidence-based policies that promote therapeutic development aimed at addressing patient needs. I enjoy tackling complex problems through in-depth analysis and broad coalition building. Some of my experiences in leading policy initiatives and cultivating internal and external partnerships include:

- development of patient-focused policy positions for a large pharmaceutical company;
- management of a diverse policy portfolio, culminating in recommendations to senior government officials;
- analysis of government, industry, and non-government policies and initiatives to ensure accurate and executable policy recommendations; and
- development of strong relationships with public- and private-sector leaders.

### **PROFESSIONAL EXPERIENCE**

#### **Pfizer, Inc.**

**Washington, DC**

Director, Innovation Policy

January 2019 – Present

Director, Science Policy and Advocacy

December 2016 – December 2018

- Primary role is the development and implementation of evidence-based policies for topics related to science, health, and innovation
- Clinical Trial Policy Lead with responsibility for policy review and development. Areas include: innovative clinical trial design, data sharing, transparency, enrollment and retention, and diversity
  - Provide support in each area through analysis of current policies and external stakeholder engagement
  - Member of the TransCelerate team on shared decision making in clinical trials
- Policy lead in support of Pfizer's Oncology Business including support of external engagements for leaders
- Digital Health Policy Lead
  - Leading a collaborative team tasked with developing Pfizer's first externally facing digital health policy
  - International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Digital Health Task Force member
- Expanded Access Policy Lead with responsibility for issues related to preapproval access and federal "Right to Try" legislation
  - Led a cross-functional team to develop external policy positions including Pfizer's gene therapy position
  - Successfully advocated the publication of statistics on Pfizer's program, making Pfizer the first pharmaceutical company to publish comprehensive metrics
- Policy analysis and development on the following topics: drug shortages, patient centricity, real world evidence, and gene therapy
- Previously managed Pfizer's Value of Medicines platform that houses 25 papers describing the burden of different diseases and the economic and societal roles that medicines play around the globe (2016-2019)

#### **White House, Office of Science and Technology Policy (OSTP)**

**Washington, DC**

Policy Advisor

September 2016 – November 2016

AAAS Science & Technology Policy Fellow

September 2014 – August 2016

- Member of the executive secretariat for President Obama's Council of Advisors on Science and Technology (PCAST), an advisory group of the nation's leading scientists and engineers who provided scientific and technical advice to the President of the United States
- Managed PCAST studies on topics including climate change, food and nutrition, forensic science, and safe drinking water. Provided support for additional studies focused on biodefense, technology for the future of cities, and technology to help an aging population
- Coordinated the development, writing, and editing of PCAST reports
- Worked with key government officials to implement PCAST policy recommendations
- Organized and executed workshops with high-level government, private sector, and non-profit leaders to provide forums for information gathering and stakeholder engagement
- Developed briefing memos for senior White House leaders on critical science and technology issues

**National Academy of Medicine, National Academies of Science**

**Washington, DC**

Program Officer, Board on Health Sciences Policy

January 2012 – August 2014

Associate Program Officer

October 2010 – December 2011

- Managed and coordinated activities for the Forum on Neuroscience and Nervous System Disorders
- Developed relationships with government, industry, academic, and patient representatives including staff of stakeholder organizations and committee members
- Analyzed and identified policy challenges and opportunities for the Committee on the Use of Chimpanzees in Biomedical and Behavioral Research; helped draft report content
- Organized, coordinated, and facilitated committee meetings and public workshops
- Drafted and edited report text, responded to reviewer comments, and prepared reports for publication
- Disseminated reports and information on the activities of the Forum
- Assisted with project development

***Hormones and Behavior Journal*, Boston University**

**Boston, MA**

Editorial Coordinator

June 2001 - February 2005

- Processed upwards of 300 manuscripts per year from submission to final publication
- Conducted all author, reviewer, and publisher correspondence
- Revamped author/reviewer correspondence system to accelerate manuscript review process
- Assigned issue content and cover artwork

**SCIENTIFIC EXPERIENCE**

**University of Pennsylvania Veterinary School**

**Philadelphia, PA**

Postdoctoral Research Fellow

December 2005 - October 2010

Laboratory of Dr. Tracy L. Bale

- Developed two unique conditional, inducible knockout mouse models to assess the impact of stress; one model focused on obesity and the other on the development of anxiety- and depression-like behaviors
- Determined the neurological, epigenetic, and metabolic consequences of moderate caloric restriction
- Defined the long term impact of prenatal stress on metabolic syndrome development and behavioral deficits

**Boston University**

**Boston, MA**

Doctoral Student

September 1999 - January 2006

Laboratories of Dr. Michael J. Baum and Dr. James A. Cherry

- Dissertation: “Assessing the contribution of the accessory olfactory system to courtship and sexual motivation in male mice”
- Biology Graduate Student Association - Co-President
- Graduate School of Arts and Science Student Organization - Vice-President
- Graduate School of Arts and Science Ethical Conduct Committee - Member

**University of Rochester Medical Center**

**Rochester, NY**

Laboratory Technician IV

August 1997 - August 1999

- Conducted research examining the effect of low-level lead exposure on attention, learning, and memory
- Managed all animal and laboratory supply ordering

**HONORS AND AWARDS**

W. E. Upjohn Award, Recognition for exceptional contribution to Pfizer	
Oncology Leader Support, Milken Institute Future of Health Summit	2019
Patient Centricity Bold Move	2019
Federal Right to Try Legislation	2018
Expanded Access Policy Position	2018
Clinical Trial Data Sharing	2018
Institute of Medicine Staff Achievement, Rookie Award	2011
Young Investigator Award, Society for the Study of Ingestive Behavior	2008

## **EDUCATION**

**Boston University**  
Ph.D. in Neuroscience

**Boston, MA**  
January 2006

**University of Rochester**  
B.S. in Biology, Concentration in Neuroscience

**Rochester, NY**  
May 1997

## **SELECTED PUBLICATIONS**

- Diana Pankevich (October 2019). “8 Steps to Achieve the Cultural Change Needed for Co-Creation with Patients.” *Clinical Leader*.
- The Value of Vaccines in Disease Prevention: A Global Perspective. 2019. Value of Medicines Platform. See: [www.pfizer.com/purpose/health-policy/value-of-medicines](http://www.pfizer.com/purpose/health-policy/value-of-medicines).
- Colleen Rye and Diana Pankevich (November 2018). “Igniting Patient Participation in Clinical Research through Technology.” Morning Consult Opinion.
- Roslyn Schneider and Diana Pankevich (November 2017). “Patients First: Beyond a Slogan, a Drive for Full Inclusion.” Huffington Post.
- Value of Medicines for Inflammatory Bowel Disease. 2018. Value of Medicines Platform.
- The Value of Cancer Medicines Worldwide. 2018. Value of Medicines Platform.
- Burden of Disease: Chronic Inflammation and Inflammatory Disease. 2017. Value of Medicines Platform.
- The Value of Medicines in Treating Leukemia. 2017. Value of Medicines Platform.
- Pankevich, D.E., Altevogt, B.M., Dunlop, J., Gage, F.H., and S.E. Hyman. (2014). “Improving and accelerating drug development for nervous system disorders.” *Neuron*. 84(3):546-53.
- Institute of Medicine (IOM). 2014. Improving and Accelerating Therapeutic Development for Nervous System Disorders – A workshop summary. Washington, DC: National Academies Press.
- IOM. 2013. Strengthening Human Resources through the Development of Candidate Core Competencies for Mental, Neurological and Substance Use Disorders in Sub-Saharan Africa – A workshop summary. Washington, DC: National Academies Press.
- IOM. 2013. Improving the Utility and Translation of Animal Models for Nervous System Disorders – A workshop summary. Washington, DC: National Academies Press.
- Altevogt, B.M., D.E. Pankevich, A.M. Pope, and J.P. Kahn. 2011. “Guiding limited use of chimpanzees in research.” *Science*. 335(6064):41-2.
- IOM. 2011. Chimpanzees in biomedical and behavioral research: Assessing the necessity. Washington, DC: The National Academies Press.
- Pankevich, D.E., S.L. Teegarden, A.D. Hedin, C.L. Jensen, and T.L. Bale. 2010. “Caloric restriction experience reprograms stress and orexigenic pathways and promotes binge-eating.” *Journal of Neuroscience*. 30(48):16399-407.
- Pankevich, D.E., and T.L. Bale. 2008. “Stress influences on motivation for a preferred food in an ethological behavioral test.” *Obesity*. 16(7):1539-44.
- Pankevich, D.E., J.A. Cherry, and M.J. Baum. 2006. “Effect of vomeronasal organ removal from male mice on their preference for and neural Fos responses to female urinary odors.” *Behav Neuroscience*. 120(4):925-36.
- Pankevich, D.E., M.J. Baum., and J.A. Cherry. 2004. “Olfactory sex discrimination persists while the preference for urinary odorants from estrous females disappears in male mice after vomeronasal organ removal.” *Journal of Neuroscience*. 24(42): 9451-9457.